Main Menu

Our research at ICR-CTSU

We lead ground-breaking, efficient, high-quality, and impactful trials across the phases, underpinned by applied methodology to drive forward clinical trial innovation.

See our clinical trials

How we work

With our innovative approach to trial design and use of novel methodologies with integral translational research, we aim to generate an evidence-base for smarter, kinder treatments.

Our applied approach ensures that trials are as informative and efficient as possible, often in challenging and complex settings. We work closely with patient partners to influence practice according to patient need, recognising the value of risk-adapted treatment in the pursuit of personally tailored medicine and long-term quality of life and survivorship. We remain committed to ensuring our trials are accessible, inclusive, and relevant for a broad range of patients.

Our expertise

Our current portfolio includes trials in breast, gynaecological & lung cancers led by Professor Judith Bliss, and urological and head and neck cancers led by Professor Emma Hall, and also spans several solid tumour sites in early phase dose-finding trials, where Professor Christina Yap’s team works in partnership with the Drug Development Unit.

Our expertise in intervention assessment includes:

  • targeted drug therapies
  • immunotherapy
  • chemotherapy
  • hormonal therapies
  • radiotherapy (including advanced targeted technologies)
  • drug-drug and drug-radiotherapy combinations
  • imaging technologies
  • diagnostics/companion diagnostics. 

Working with investigators across the UK and abroad, we have experience in:

  • successful development, implementation and delivery of basket, umbrella and platform trial designs
  • novel early phase designs
  • Bayesian designs in rare cancers
  • interventional cohort studies for de-escalation trials
  • the incorporation of biomarkers into trial design and treatment selection.

Maximising our data use

We maximise the use of our participants' datawith the aim of gaining further understandings of mechanisms of action and markers of treatment sensitivity or resistance. Dr Maggie Cheang’s team of statistical, computational and translational scientists identifies clinically relevant biomarkers and aims to develop reliable contextual-based AI algorithms integrating -omics data with patient outcomes.

Methodology research

Our applied clinical trials methodology research investigates best practice in trial design, conduct, analysis and reporting. Areas of interest include imaging biomarkers, patient reported outcomes, and use of information routinely collected by the NHS to streamline trial data collection.

We are also exploring enhanced methods for patient and public involvement and initiatives to improve equality, diversity and inclusion.

PhD studentships

Our PhD studentshipsbenefit from inter-disciplinary clinical and methodology supervisory teams. Students are involved in real-life development and implementation of novel aspects in our clinical trials.

Our clinical trials

Find out about our clinical trials.

Our clinical trials

Clinical trials methodology research

Our applied methodology research portfolio investigates best practice in trial design, conduct, analysis and reporting.

Clinical trials methodology

Early phase adaptive designs

We aim to help get new drugs safely, effectively, and as quickly as possible to patients for whom they can be life-changing.

Early phase adaptive designs

Integrative genomic analysis and digital pathology

We analyse large datasets generated from clinical trial samples to study the underlying biology of tumours.

Integrative genomic analysis and digital pathology

Clinical trials